Key result
HDL raising therapies represent a promising therapeutic target for managing coronary artery disease risk, though larger clinical trials are ongoing to confirm their benefits.
Why the study?
High density lipoprotein has become a new therapeutic target after low density lipoprotein in managing risk factors of coronary artery disease despite existing therapies.
Answers are grounded in this paper and cite their sources.
Coronary artery disease (CAD) is one of the most important causes of morbidity and mortality worldwide despite considerable therapeutic advances that control the risk factors. Numerous clinical trials have shown an inverse association between high density lipoprotein cholesterol levels and the risk of coronary artery disease. So, high density lipoprotein has become a new therapeutic target after low density lipoprotein in the management of risk factors of coronary artery disease. In this review, we explore existing and future treatment strategies along with their benefits and failures which will guide our management strategy. HDL raising therapies showed very promising results in many clinical trials but larger clinical trials are ongoing DOI: http://dx.doi.org/10.3329/cardio.v5i1.12277 Cardiovasc. j. 2012; 5(1): 73-80
No takes yet. Share an insight, caveat, or question.
Ali et al. (2012) conducted a review in Coronary artery disease. HDL raising therapies was evaluated. HDL raising therapies represent a promising therapeutic target for managing coronary artery disease risk, though larger clinical trials are ongoing to confirm their benefits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: